At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Posaconazoledrug
Likely dose
Posaconazole 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label, Phase II Study Investigating the Efficacy of Posaconazole as Prophylaxis Antifungal Agent in Aplastic Anemia / Hypoplastic Myelodysplastic Syndrome Patients Undergoing Antithymocyte Globulin Treatment
In Brief
A Phase 2 clinical trial evaluating Posaconazole for Aplastic Anemia and 2 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
To investigate the efficacy of posaconazole as prophylaxis antifungal agent in aplastic anemia / hypoplastic myelodysplastic syndrome (AA/hMDS) patients undergoing antithymocyte globulin (ATG) treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAplastic Anemia, Myelodysplastic Syndromes, Fungal Infection
CountriesSouth Korea
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartApr 2018
Primary CompletionJul 2023
TodayJul 2026
First PostedOct 23, 2017
Enrollment StartApr 20, 2018
Primary CompletionJul 15, 2023
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 8.7 years ago
Interventions
Posaconazoledrug
Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks \*if posaconazole tablet intolerance: posaconazole suspension 200mg tid